January 2012 in “Human health handbooks” The document discussed the challenges and treatment options for scalp psoriasis, a condition affecting 50–75% of psoriasis patients, characterized by erythematosquamous lesions and silver-white scaling. Scalp psoriasis was noted to impair quality of life and cause psychological distress. Despite numerous therapies, treatment remained difficult due to the scalp's inaccessibility and the unpleasantness of topical applications. Shampoos, containing keratolytics, tars, and corticosteroids, were highlighted as safe, well-tolerated, and effective, with clobetasol propionate shampoo and tar-blend shampoos being preferred for induction and maintenance therapy, respectively. Treatment needed to be individualized as no single preparation was superior in all situations.
The document discussed the challenges and treatment options for scalp psoriasis, a condition affecting 50-75% of psoriasis patients and characterized by erythematosquamous lesions and silver-white scaling. Scalp psoriasis could impair hair growth and significantly impact quality of life due to pruritus, scaling, and psychological distress. Despite numerous therapies, treatment was difficult due to the scalp's inaccessibility and the unpleasantness of topical applications. Shampoos, containing keratolytics, tars, and corticosteroids, were highlighted as safe, well-tolerated, and effective, with clobetasol propionate shampoo and tar-blend shampoos being preferred for induction and maintenance therapy, respectively. However, no single preparation was universally superior, necessitating individualized treatment plans.
1 citations
,
January 2009 in “Actas Dermo-Sifiliográficas” Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.
128 citations
,
January 2001 in “American Journal of Clinical Dermatology” Coal tar shampoos, salicylic acid, and topical corticosteroids are effective for scalp psoriasis, with Vitamin D3 analogues also showing benefits; severe cases may require stronger medication with more risks.
COVID-19 can lead to different skin symptoms and might trigger autoimmune diseases in genetically susceptible people.